Quotes 5-day view Delayed Nasdaq
01/31/2023
02/01/2023
02/02/2023
02/03/2023
02/06/2023
Date
2.95(c)
3.11(c)
3.28(c)
3.4(c)
3.26
Last
258 994
454 768
448 095
935 398
179 628
Volume
-1.99%
+5.42%
+5.47%
+3.66%
-4.12%
Change
Estimated financial data (e) (USD)
Sales 2022
0,96 M
-
-
Net income 2022
-55,3 M
-
-
Net Debt 2022
-
-
-
P/E ratio 2022
-0,02x
Yield 2022
-
Sales 2023
-
-
-
Net income 2023
-19,2 M
-
-
Net Debt 2023
-
-
-
P/E ratio 2023
-0,77x
Yield 2023
-
Capitalization
1,89 M
1,89 M
-
Capi. / Sales 2022
1,97x
Capi. / Sales 2023
-
Nbr of Employees
80
Free-Float
99,7%
Baudax Bio, Inc. is a pharmaceutical company. The Company is primarily focused on commercializing and developing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO (meloxicam) injection. ANJESO is a preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities. This injectable form of IV meloxicam, utilizes NanoCrystal...
All news about BAUDAX BIO, INC.
02/01 Certain common stock of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1.. CI
02/01 Certain warrants of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB.. CI
02/01 Certain restricted stock units of Baudax Bio, Inc. are subject to a Lock-Up Agreement E.. CI
02/01 Certain options of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-.. CI
01/24 Baudax Bio, Inc. : Other Events, Financial Statements and Exhibits (form 8-K) AQ
01/24 Top Midday Gainers MT
01/24 Baudax Bio Reports Positive Outcome of Initial Analysis in Phase 2 Trial of BX1000; Sha.. MT
01/24 Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial .. AQ
01/24 Baudax Bio, Inc. Announces Positive Outcome of Interim Analysis of Phase Ii Randomized .. CI
01/09 Baudax Bio : Corporate Overview PU
01/09 Baudax Bio, Inc. : Other Events, Financial Statements and Exhibits (form 8-K) AQ
01/04 North American Morning Briefing: Futures Rise -2- DJ
01/03 Noble Capital Downgrades Baudax Bio to Market Perform Rating From Outperform MT
2022 Baudax Bio, Inc. : Other Events (form 8-K) AQ
2022 Top Premarket Gainers MT
News in other languages on BAUDAX BIO, INC.
Analyst Recommendations on BAUDAX BIO, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BAUDAX BIO, INC.
Short Term Mid-Term Long Term Trends Neutral Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
-
Number of Analysts
0
Last Close Price
3,40 $
Average target price
24,00 $
Spread / Average Target
606%
Please enable JavaScript in your browser's settings to use dynamic charts.